| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Merck's new AI commercial strategy 'reimagining engagement with HCPs' | ||
| Mi | AbbVie to establish NC production base with $1.4B investment, creating 730-plus jobs | ||
| Mi | Amneal seizes 'golden era' for biosims with $1.1B Kashiv buyout | ||
| Mi | Samsung Biologics posts massive revenue growth as labor union rally sets strike in motion | ||
| Mi | Merck goes with Google for AI push, striking enterprise partnership worth up to $1B | ||
| Mi | Novartis launches 'Sjöut for Sjögren's' campaign, teams with Carrie Ann Inaba | ||
| 21.04. | Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso | ||
| 21.04. | The Oral GLP-1 Tracker: Following the launch trajectories of Lilly's Foundayo, Novo's Wegovy pill | ||
| 21.04. | Pfizer's strategy head Andrew Baum to step down following brief tenure: reports | ||
| 21.04. | AstraZeneca eyes 5th Ultomiris indication after kidney disease trial win | ||
| 21.04. | In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer | ||
| 21.04. | UCB partners with Myasthenia Gravis Foundation of America on meal program targeting nutrition deserts | ||
| 20.04. | Genentech shifts Hemlibra marketing focus to patient stories as competition approaches | ||
| 20.04. | Neurogene hires new CCO as it eyes commercial future for its Rett gene therapy | ||
| 20.04. | Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike | ||
| 20.04. | Biovac nets $108M finance package to build Africa's first fully integrated vaccine plant | ||
| 20.04. | Biogen bullish on America with Durham Bulls team up | ||
| 20.04. | Bayer falls short in bid to block J&J's survival claims in prostate cancer clash | ||
| 20.04. | AbbVie launches 'PSO Done' psoriasis campaign with cross-agency effort | ||
| 20.04. | Theramex exits self-regulatory body after 'systemic' compliance failures | ||
| 17.04. | FDA's accelerated approval pathway needs stronger transparency, evidence standards: ICER | ||
| 17.04. | Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat | ||
| 17.04. | Fierce Pharma Asia-Astellas' stem cell therapy rethink; GSK's bullish ADC plan; Daiichi's OTC sale | ||
| 17.04. | BIO comes out swinging with 'Fight of Our Lives' campaign for the industry's 50th birthday | ||
| 16.04. | Viatris, Teva kick off separate recalls over dissolution, raw material issues |